{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:23Z","timestamp":1792839623434,"version":"4.5.0"},"reference-count":157,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jhep.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:04:57Z","timestamp":1666224297000},"page":"430-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases\u2020"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-5112","authenticated-orcid":false,"given":"Frederik","family":"Nevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-8856","authenticated-orcid":false,"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.10.007_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bpg.2018.09.001","article-title":"PBC-transplantation and disease recurrence","volume":"34\u201335","author":"Nevens","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"10319","key":"10.1016\/j.jhep.2022.10.007_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"6\u20137","key":"10.1016\/j.jhep.2022.10.007_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clinre.2011.02.007","article-title":"Liver transplantation in PBC and PSC: indications\u00a0and disease recurrence","volume":"35","author":"Carbone","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bpg.2011.09.010","article-title":"Genetics in primary sclerosing cholangitis","volume":"25","author":"Folseraas","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng.3745","article-title":"Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease","volume":"49","author":"Ji","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib6","article-title":"Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis","volume":"3","author":"Dyson","year":"2020","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.31311","article-title":"The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications","volume":"72","author":"Dean","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jhep.2021.04.055","article-title":"An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs","volume":"75","author":"Cordell","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"NEJM"},{"key":"10.1016\/j.jhep.2022.10.007_bib10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2010.09.004","article-title":"Pathogenesis of cholestatic liver disease and therapeutic approaches","volume":"139","author":"Hirschfield","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular physiology of bile acid signaling in health, disease, and aging","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib12","first-page":"87","article-title":"Histopathology of vanishing bile duct diseases","volume":"2","author":"Desmet","year":"1998","journal-title":"Adv Clin Path"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib13","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"POISE study group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"NEJM"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib18","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib19","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.14309\/ajg.0000000000001285","article-title":"A\u00a0comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis","volume":"116","author":"Goet","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.10.007_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","author":"Corpechot","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib22","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/jgh.14929","article-title":"Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis","volume":"35","author":"Joshita","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis","volume":"55","author":"Osman","year":"2021","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstr\u00f6m","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib26","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib27","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib29","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.10.007_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2009.12.002","article-title":"The new therapeutic frontier-nuclear receptors and the liver","volume":"52","author":"Karpen","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010715-103209","article-title":"Nuclear receptors as therapeutic targets in liver disease: are we there yet?","volume":"56","author":"Rudraiah","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jhep.2022.10.007_bib33","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2022.10.007_bib34","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2022.10.007_bib35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cel"},{"key":"10.1016\/j.jhep.2022.10.007_bib36","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib37","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","article-title":"Interactions between the intestinal microbiome and liver diseases","volume":"146","author":"Schnabl","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.007_bib38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.10.007_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jhep.2022.10.007_bib40","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.10.007_bib41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.10.007_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.27927","article-title":"Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.jhep.2022.10.007_bib43","first-page":"136","article-title":"Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features","volume":"46","author":"Olsson","year":"1999","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib44","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhep.2022.10.007_bib45","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2020.12.019","article-title":"Bezafibrate for the treatment of cholestatic pruritus: time for a change in management?","volume":"160","author":"Dyson","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib49","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib50","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib51","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1476-5381.2008.00030.x","article-title":"Nuclear receptors as therapeutic targets in cholestatic liver diseases","volume":"156","author":"Zollner","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhep.2022.10.007_bib54","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor \u03baB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"17","key":"10.1016\/j.jhep.2022.10.007_bib56","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib58","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO-3 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib59","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib60","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib61","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169331","article-title":"Farnesoid X receptor activation attenuates intestinal ischemia reperfusion injury in rats","volume":"12","author":"Ceulemans","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib64","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2019.06.017","article-title":"FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis","volume":"71","author":"Sorribas","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR ligands: current status and clinical applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib66","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","article-title":"Steroidal or non-steroidal FXR agonists - is that the question?","volume":"66","author":"Verbeke","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2022.10.007_bib69","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cells8060536","article-title":"FGF19-FGFR4 signaling in hepatocellular carcinoma","volume":"8","author":"Raja","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2022.10.007_bib70","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib71","doi-asserted-by":"crossref","first-page":"17210","DOI":"10.1038\/s41598-018-35496-z","article-title":"Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from fibrosis and hepatocarcinogenesis","volume":"8","author":"Gadaleta","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.10.007_bib72","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"issue":"247","key":"10.1016\/j.jhep.2022.10.007_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009098","article-title":"A\u00a0nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2022.10.007_bib74","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2022.10.007_bib75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib76","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2022.10.007_bib77","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2022.10.007_bib78","first-page":"19","article-title":"The role of PPAR-\u03b4 in metabolism, inflammation, and cancer: many characters of a critical transcription factor","author":"Liu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2022.10.007_bib79","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2022.10.007_bib80","first-page":"695","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells","volume":"118","author":"Arenas","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2022.10.007_bib81","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0016-5085(86)90859-0","article-title":"Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents","volume":"90","author":"Yoon","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.007_bib82","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-\/- mice","volume":"49","author":"Halilbasic","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in mdr2 (ABCB4)knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.007_bib84","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/j.gastro.2011.09.051","article-title":"Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury","volume":"142","author":"Moustafa","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib85","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation","volume":"75","author":"Zhu","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib86","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.31236","article-title":"Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis","volume":"72","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib87","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jhep.2018.04.009","article-title":"Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis","volume":"69","author":"Pollheimer","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib88","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.freeradbiomed.2012.05.007","article-title":"Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4\/NOX1 inhibitor in\u00a0vivo","volume":"53","author":"Jiang","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib89","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib90","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.007_bib91","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/gut.52.9.1239","article-title":"Inappropriate ileal conservation of bile acids in cholestatic liver disease: homeostasis gone awry","volume":"5","author":"Hofmann","year":"2003","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.jhep.2022.10.007_bib92","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2022.10.007_bib93","first-page":"8","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","author":"Yu","year":"2019","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib94","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0041-1730923","article-title":"MRGPRX4 in cholestatic pruritus","volume":"41","author":"Yu","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.10.007_bib95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jsbmb.2015.10.019","article-title":"GABAA receptor modulating steroid antagonists (GAMSA) are functional in\u00a0vivo","volume":"160","author":"Johansson","year":"2016","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2021.03.012","article-title":"A\u00a0pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy","volume":"75","author":"Montagnese","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib97","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2022.10.007_bib98","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","article-title":"Systematic review: ursodeoxycholic acid\u2013adverse effects and drug interactions","volume":"18","author":"Hempfling","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jhep.2022.10.007_bib99","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"22","key":"10.1016\/j.jhep.2022.10.007_bib100","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A\u00a0multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"NEJM"},{"issue":"8","key":"10.1016\/j.jhep.2022.10.007_bib101","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","article-title":"Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis","volume":"69","author":"Harms","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib102","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/hep.21795","article-title":"Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study","volume":"46","author":"Jackson","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib103","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.007_bib104","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cgh.2017.09.062","article-title":"Twenty-Year comparative analysis of patients with autoimmune liver\u00a0diseases on transplant Waitlists","volume":"16","author":"Webb","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib106","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2022.10.007_bib107","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib108","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib109","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2022.10.007_bib111","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib112","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.16181","article-title":"Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid","volume":"53","author":"Gomez","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib113","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.jhepr.2021.100248","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D'Amato","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.10.007_bib114","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact\u00a0of\u00a0obeticholic acid exposure on decompensation and mortality in\u00a0primary biliary cholangitis and cirrhosis","volume":"5","author":"John","year":"2021","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib115","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib116","first-page":"489","article-title":"Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials","volume":"32","author":"Agrawal","year":"2019","journal-title":"Ann Gastroenterol"},{"issue":"23","key":"10.1016\/j.jhep.2022.10.007_bib117","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib118","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib119","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A\u00a0prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib120","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib121","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib122","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2022.10.007_bib123","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/apt.16618","article-title":"Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up","volume":"54","author":"Sorda","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib124","first-page":"1061","article-title":"Real-world clinical management of patients with primary biliary cholangitis-A retrospective multicenter study from Germany","volume":"10","author":"Wilde","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2022.10.007_bib125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jhep.2022.10.007_bib126","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib127","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.10.007_bib128","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A\u00a0randomized placebo-controlled Trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.10.007_bib131","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.10.007_bib132","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib133","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Budesonide in the treatment of patients with primary biliary cirrhosis with\u00a0a\u00a0suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib134","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2022.10.007_bib135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A\u00a0placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib136","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","article-title":"Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders","volume":"14","author":"Karpen","year":"2020","journal-title":"Hepatol Int"},{"issue":"8","key":"10.1016\/j.jhep.2022.10.007_bib137","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/liv.14553","article-title":"Potential of ileal bile acid\u00a0transporter inhibition as a therapeutic target in Alagille syndrome\u00a0and\u00a0progressive familial intrahepatic cholestasis","volume":"40","author":"Kamath","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.10.007_bib138","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1021\/jm400459m","article-title":"Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes","volume":"56","author":"Wu","year":"2013","journal-title":"J\u00a0Med Chem"},{"issue":"10074","key":"10.1016\/j.jhep.2022.10.007_bib139","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"issue":"10311","key":"10.1016\/j.jhep.2022.10.007_bib140","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2022.10.007_bib141","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","author":"Al-Dury","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib142","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","article-title":"Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study","volume":"45","author":"Baumann","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib143","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib144","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2022.10.007_bib145","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2022.10.007_bib146","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.10.007_bib147","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"1","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib148","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib149","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasisand liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.10.007_bib150","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib151","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2022.10.007_bib152","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.007_bib153","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and safety of Cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","volume":"5","author":"Eksteen","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.10.007_bib154","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2022.10.007_bib155","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/hep.31613","article-title":"Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate","volume":"73","author":"Smets","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2022.10.007_bib156","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jhep.2022.10.007_bib157","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822031439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822031439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:15Z","timestamp":1759175235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822031439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":157,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0168827822031439"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.10.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases\u2020","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}